SBHMY (Sino Biopharmaceutical) Growth Rank : 7 (As of Apr. 09, 2025)

View and export this data going back to 2014. Start your Free Trial

What is Sino Biopharmaceutical Growth Rank?

Sino Biopharmaceutical has the Growth Rank of 7.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Competitive Comparison of Sino Biopharmaceutical's Growth Rank

For the Biotechnology subindustry, Sino Biopharmaceutical's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sino Biopharmaceutical's Growth Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's Growth Rank distribution charts can be found below:

* The bar in red indicates where Sino Biopharmaceutical's Growth Rank falls into.

Save Embed

;

Save Embed

;

Sino Biopharmaceutical Growth Rank Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Sino Biopharmaceutical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (OTCPK:SBHMY) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

SBMFF:USA 01177:Hong Kong SMZ1:Germany

Address

1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG

Website

https://www.sinobiopharm.com

Listed on the Hong Kong Stock Exchange in 2000, Sino Biopharmaceutical is one of the largest Chinese drugmakers. It started with generic drug manufacturing. Since 2018, Sino Biopharm has been actively pivoting into an innovative drugmaker after the Chinese government launched its volume-based procurement policy for the healthcare industry. As of 2023, 37.8% of the firm's total revenue comes from five innovative drugs and five biosimilar drugs. Sino Biopharm's biggest revenue segment is oncology medicines, accounting for 33.6% of total revenue, followed by hepatitis, surgery/analgesia, respiratory, and cardio-cerebral vascular therapeutic areas.